United Therapeutics (UTHR) Tops Q2 EPS by 22c
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $547.15 +0.98%
EPS Growth %: +11.9%
Financial Fact:
Operating income: 238.6M
Today's EPS Names:
CRMT, FOMI, FLES, More
EPS Growth %: +11.9%
Financial Fact:
Operating income: 238.6M
Today's EPS Names:
CRMT, FOMI, FLES, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $1.34, $0.22 better than the analyst estimate of $1.12. Revenue for the quarter came in at $225.6 million versus the consensus estimate of $213.33 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump discloses over $1.4 billion in crypto income in 2025 filing
- William Blair on TransMedics Group (TMDX): 'We believe TransMedics’ second-quarter sales will exceed consensus estimates'
- Biogen expects $164M R&D charge to hit Q2 2026 earnings
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
